Physician profile
Subhash Mishra
NPI 1285695437
$13,787.04
in general payments reported to CMS, 2019-2025
44 companies · $1,206 in 2025
The $1,206 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,405 · 2020: $2,233 · 2021: $2,387 · 2022: $2,361 · 2023: $2,297 · 2024: $1,898 · 2025: $1,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,400.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,704.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,697.20 | 2021-2025 | |
| Pfizer INC. | $1,329.09 | 2019-2025 | |
| Amgen INC. | $1,178.95 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $1,091.69 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $622.20 | 2020-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $598.63 | 2019-2024 | Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $574.15 | 2022-2025 | |
| Glaxosmithkline, LLC. | $547.84 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $516.10 | 2019-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $461.00 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $409.59 | 2019-2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $398.83 | 2022 | |
| Merck Sharp & Dohme LLC | $294.49 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $267.52 | 2020-2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subhash Mishra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.